Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Shire considers Takeda's revised £46bn takeover offer Shire’s board said that it is willing to recommend Takeda Pharmaceutical’s revised acquisition offer of £46bn to its shareholders. Production & Manufacturing > Manufacturing > News
FDA expands GSK’s Trelegy Ellipta indication in COPD The US Food and Drug Administration (FDA) has approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’) to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who had an acute worsening of respiratory symptoms.
Regulatory Affairs > News AstraZeneca’s lung cancer combo fails in phase III trial AstraZeneca’s lung cancer combo of Imfinzi (durvalumab) plus tremelimumab has failed to deliver desired results in a phase III trial, called ARCTIC, in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had more than two prior treatments.
Contract Research & Services > Clinical Trials > News Shire considers Takeda's revised £46bn takeover offer By PBR Staff Writer
Shire’s board said that it is willing to recommend Takeda Pharmaceutical’s revised acquisition offer of £46bn to its shareholders.
Production & Manufacturing > Manufacturing > News
Prothena scraps development of AL amyloidosis drug By PBR Staff Writer
Prothena is stopping the development of AL amyloidosis treatment NEOD001 following unfavorable results in the phase 2b Pronto study.
Contract Research & Services > Clinical Trials > News Celgene expands bispecific antibody collaboration with Zymeworks Zymeworks said that Celgene has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using the former’s Azymetric platform.
Drug Research > Drug Discovery & Development > News Scientists develop new method to make drugs smarter Scientists from the University of Lincoln in the UK have created a new technique using nanotechnology which can make drugs more effective at reaching their target.
Drug Research > Drug Discovery & Development > News

Latest News and Insight by Sector

Production & Manufacturing

Shire considers Takeda's revised £46bn takeover offer
By PBR Staff Writer
Shire’s board said that it is willing to recommend Takeda Pharmaceutical’s revised acquisition offer of £46bn to its shareholders.
Production & Manufacturing > Manufacturing > News
Synpromics to partner with Lonza to improve biopharmaceuticals manufacturing
Synpromics has partnered with Lonza Pharma & Biotech to further develop its inducible promoter system and enhance manufacturing of biopharmaceuticals.
Production & Manufacturing > Manufacturing > News

Drug Research

Celgene expands bispecific antibody collaboration with Zymeworks
Zymeworks said that Celgene has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using the former’s Azymetric platform.
Drug Research > Drug Discovery & Development > News
Scientists develop new method to make drugs smarter
Scientists from the University of Lincoln in the UK have created a new technique using nanotechnology which can make drugs more effective at reaching their target.
Drug Research > Drug Discovery & Development > News

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn
Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

AstraZeneca’s lung cancer combo fails in phase III trial
AstraZeneca’s lung cancer combo of Imfinzi (durvalumab) plus tremelimumab has failed to deliver desired results in a phase III trial, called ARCTIC, in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had more than two prior treatments.
Contract Research & Services > Clinical Trials > News
Prothena scraps development of AL amyloidosis drug
By PBR Staff Writer
Prothena is stopping the development of AL amyloidosis treatment NEOD001 following unfavorable results in the phase 2b Pronto study.
Contract Research & Services > Clinical Trials > News

Automation

Illumina Reports Financial Results for First Quarter of Fiscal Year 2018
Illumina, Inc. announced its financial results for the first quarter of fiscal year 2018.
News
Horizon Discovery out-licenses cell line engineering technology to US firm
Horizon Discovery Group has entered into a non-exclusive out-licensing agreement with an undisclosed US-based immuno-oncology company (the Partner) for its technologies to support the development and manufacture of a biomanufacturing cell line for commercial use.
Automation > IT & Software > News

Regulatory Affairs

FDA expands GSK’s Trelegy Ellipta indication in COPD
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’) to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who had an acute worsening of respiratory symptoms.
Regulatory Affairs > News
Pfizer biosimilar of Roche's cancer drug fails to get FDA approval
By PBR Staff Writer
The US Food and Drug Administration (FDA) has declined to approve Pfizer’s proposed biosimilar of Roche’s breast cancer drug Herceptin (trastuzumab) and asked for more technical information.
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery